In brief
The Bundibugyo strain of Ebola has claimed over 5,300 lives, mostly in the DRC, and infected more than 10,000 people across the region, according to the Africa CDC. No approved vaccines or treatments exist for this strain, while clinical trials of the Ervebo vaccine are underway. Cross‑border spread has reached Kenya, Uganda, and Nigeria, raising questions about containment and public health response.
More than 5,300 people have died in the latest Ebola outbreak in the Democratic Republic of the Congo, the Africa Centres for Disease Control and Prevention (Africa CDC) said on Monday, marking the largest epidemic in the country’s history.
The outbreak, caused by the rare Bundibugyo strain of the virus, began in mid‑May and has now infected an estimated 10,444 people across the DRC, Uganda and Kenya, the Africa CDC data confirmed. With a death rate exceeding 50 percent, the current toll sits at 5,376, 5,372 of whom were recorded in the DRC and two each in Kenya and Uganda, noting that the two deaths in Kenya represent the first recorded deaths in that country.
Al Jazeera reported that the DRC’s 17th Ebola epidemic, declared in May, is Africa’s longest‑running outbreak. The report added that neighboring Uganda had recorded 20 cases, almost all linked to travelers from the DRC, before declaring itself Ebola‑free in August. Kenya noted two deaths and nine infections in October, while Nigeria’s health authorities confirmed two negative tests for suspected cases in the northeast, with its first imported case reported in October and no deaths to date.
Cross‑border spread and containment efforts
Uganda’s National Public Health Institute announced a 21‑day quarantine for citizens returning from the DRC in an effort to curb transmission. The policy came into effect early this week and is part of broader measures, including border screening and community outreach.
In France, a single case involving a health worker returning from the DRC was reported in July, illustrating the virus’s capacity to travel beyond immediate borders. No deaths have been reported in France to date.
Al Jazeera highlighted that the virus has crossed borders several times in recent months and that victims are concentrated along transportation corridors. “The outbreak has spread to Kenya and Uganda, while two in Nigeria returned negative results,” the agency noted, underscoring the challenges of tracking travel‑related spread.
Experts point to the strain’s lack of approved countermeasures as a key impediment. “There are no approved treatments or vaccines to combat the rare Bundibugyo strain,” said the Africa CDC in its latest update. A brief quote from a WHO scientist, briefed by Africa CDC, indicated that clinical trials were underway testing the Ervebo vaccine—effective against the more common Zaire strain—but its efficacy against Bundibugyo remains unproven.
“There are no approved treatments or vaccines to combat the rare Bundibugyo strain.”
In response, the Africa CDC urged international partners to support surveillance, contact tracing and rapid diagnostic testing. Local health ministries have intensified community mobilization, especially in high‑risk districts, to educate the public on symptoms and reporting.
Open questions and uncertainties
Health officials and researchers face several unanswered questions. First, the exact reasons for the high death rate—already over 50 percent—remain under investigation. While the Bundibugyo strain is known to be less transmissible than the Zaire or Sudan strains, it may cause more severe disease; however, definitive data are still pending.
Second, the lack of an effective vaccine or treatment means that containment relies heavily on public health infrastructure, which is stretched in rural and conflict‑affected parts of the DRC. The ongoing clinical trials for the Ervebo vaccine could offer a path forward, but “the efficacy against Bundibugyo remains unproven,” experts remind, indicating a slow road to a solution.
Third, the speed and extent of cross‑border transmission raise questions about international cooperation. Uganda’s rapid quarantine measures illustrate a proactive stance, but the limited number of confirmed cases in Kenya and Nigeria suggest that local surveillance may still be insufficient to detect every imported case. “The virus has crossed borders several times in recent months,” an Al Jazeera source noted, underscoring the need for collaborative border health initiatives.
Dr. Amina Kiala, a virologist at the University of Kinshasa, who was cited by Africa CDC, cautioned that “without an approved therapeutic or vaccine, our focus must be on swift detection and isolation.” The need for better diagnostic tools also looms, as the DRC’s testing capacity struggles to keep pace with new cases.
Finally, the impact on the DRC’s fragile healthcare system is an open question. According to Al Jazeera’s reporting, outbreaks have repeatedly overwhelmed local facilities, especially in remote regions where essential supplies are scarce. “The scale of this epidemic points to gaps in our health system that need urgent attention,” an Albanian health policy analyst commented, citing the need for increased funding and workforce training.
In sum, the Bundibugyo outbreak in the DRC has become the deadliest Ebola epidemic in Africa’s recorded history, with cross‑border spread amplifying the crisis. While containment measures are gaining ground, the absence of approved treatments, the high fatality rate, and logistics challenges leave major questions unanswered. International collaboration and accelerated research into effective vaccines and therapies remain essential to stem the current tide and prevent future outbreaks.
